DPP-4 inhibitors for type 2 diabetes: an overview of systematic reviews_Chinese Journal of Evidence-Based Medicine

Authors：

LING Juan ^1,2,3 , ZHANG Dinghua ⁴ , DOU Yinghuan ⁵ , XIE Zhuolin ⁶ , GE Long ^1,2,3,7 , WANG Yongfeng ⁸ , XUN Yangqin ^1,2,3,9 , TIAN Jinhui ^1,2,3 ,  YANG Kehu ^1,2,3

1. Evidence-Based Medicine Center, Lanzhou University, Lanzhou, 73000, P.R.China;
2. Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, 73000, P.R.China;
3. The GRADE Center in China, Lanzhou, 73000, P.R.China;
4. Department of Endocrinology, Gansu Province Hospital of Traditional Chinese Medicine, Lanzhou, 73000, P.R.China;
5. School of Basic Medical Sciences, Lanzhou University, Lanzhou, 73000, P.R.China;
6. Gansu University of Traditional Chinese Medicine, Lanzhou, 73000, P.R.China;
7. The First Clinical Medical College, Lanzhou University, Lanzhou, 73000, P.R.China;
8. School of Basic Medical Sciences, Gansu University of Traditional Chinese Medicine, Lanzhou, 73000, P.R.China;
9. School of Public Health, Lanzhou University, Lanzhou, 73000, P.R.China;

Corresponding author：

YANG Kehu, Email: kehuyangebm2006@126.com

Keywords：

Dipeptidyl peptidase-4 inhibitor; Type 2 diabetes mellitus; Overview of systematic review; AMSTAR; PRISMA

DOI：

10.7507/1672-2531.201706017

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectiveTo overview the systematic reviews/meta-analyses (SRs/MAs) of efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP-4) in treatment of type 2 diabetes mellitus (T2DM).MethodsDatabase including The Cochrane Library, PubMed, EMbase, CBM, WanFang Data and CNKI were searched from inception to December 2016 to collect SRs/MAs of randomized controlled trials (RCTs) of DPP-4 for the treatment of T2DM. Two reviewers independently screened literature, extracted data, and evaluated the reporting and methodological qualities using the PRISMA checklist and the AMSTAR tool.ResultsTwenty-seven SRs/MAs of DPP-4 for the treatment of T2DM were included in this overview. The average score of AMSTAR was 7.04. The worst score were the item 1 (26 studies didn't provide an ‘a priori’ design), item 4 (10 studies didn't provide whether the status of publication used as an inclusion criterion?), item 10 and item 11 (15 studies didn't assess the likelihood of publication bias and the potential conflicts of interest). The PRISMA score ranged from 17.0 to 24.5. The main problems of reporting were protocol and registration, search, additional analyses and funding.ConclusionThe evidence shows that the reporting and methodological quality of the SRs/MAs of DPP-4 inhibitors for type 2 diabetes are not high.

Citation： LING Juan, ZHANG Dinghua, DOU Yinghuan, XIE Zhuolin, GE Long, WANG Yongfeng, XUN Yangqin, TIAN Jinhui, YANG Kehu. DPP-4 inhibitors for type 2 diabetes: an overview of systematic reviews. Chinese Journal of Evidence-Based Medicine, 2018, 18(2): 208-215. doi: 10.7507/1672-2531.201706017 Copy

1.	International Diabetes Federation. IDF Diabetes Atlas 7th Edition. Available at: https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/13:diabetes-atlas-seventh-edition.html.
2.	Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among men and women in China. N Engl J Med, 2010, 362(25): 2425.
3.	Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359(15): 1577-1589.
4.	Thornberry NA, Weber AE. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem, 2007, 7 (6): 557-568.
5.	Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther, 2009, 26(3): 249-262.
6.	Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem, 2007, 50(26): 6450-6453.
7.	Feng J, Zhang ZY, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem, 2007, 50(10): 2297-2300.
8.	Shea BJ, Bouter LM, Peterson J, et al. External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS One, 2007, 2(12): e1350.
9.	熊俊, 陈日新. 系统评价/Meta分析方法学质量的评价工具 AMSTAR. 中国循证医学杂志, 2011, 11(9): 1084-1089.
10.	Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ, 2009, 339(10): e1-e34.
11.	Zhou JB, Bai L, Wang Y, et al. The benefits and risks of DPP4-IV-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial. Int J Clin Pract, 2016, 70(2): 132-141.
12.	Loh HH, Yee A, Loh HS, et al. Comparative studies of dipeptidyl peptidase 4 inhibitor vs. sulphonylurea among muslim type 2 diabetes patients who fast in the month of ramadan: a systematic review and meta-analysis. Prim Care Diabetes, 2016, 10(3): 210-219.
13.	李军, 唐川, 薛耀明. 胰高血糖素样肽-1 受体激动剂与二肽基肽酶-4 抑制剂治疗 2 型糖尿病的比较研究—系统评价和 Meta 分析. 中国急救医学, 2015, 35(z2): 222-225.
14.	Cai X, Han X, Luo Y, et al. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on beta-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis. J Diabetes, 2015, 7(3): 347-359.
15.	周玥, 何梅, 杨明, 等. GLP-1 受体激动剂与 DPP-4 抑制剂比较治疗 2 型糖尿病效果的系统评价. 中国循证医学杂志, 2014, 14(12): 1459-1466.
16.	Zhang Y, Hong J, Chi J, et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas-a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev, 2014, 30(3): 241-256.
17.	Park H, Park C, Kim Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother, 2012, 46(11): 1453-1469.
18.	Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab, 2012, 14(12): 1061-1072.
19.	Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther, 2012, 34(6): 1247.
20.	Monami M, Iacomelli I, Marchionni N, et al. Dipeptydil [dipeptidyl] peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis, 2010, 20(4): 224-235.
21.	徐晓菲, 吴玉波, 吴禹蒙. 西格列汀对 2 型糖尿病患者血脂水平影响的系统评价. 中国药房, 2015, 26(6): 784-787.
22.	李寅辉, 李凯利, 刘浩. 西格列汀治疗 2 型糖尿病药理作用的 Meta 分析. 循证医学, 2015, 15(3): 149-154.
23.	Wang T, Gou Z, Wang F, et al. Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. PLoS One, 2014, 9(8): e103798.
24.	万里燕, 张策, 郭伟宏, 等. 西格列汀治疗 2 型糖尿病疗效和安全性的 Meta 分析. 药物不良反应杂志, 2013, 15(6): 306-313.
25.	Du Q, Wu B, Wang YJ, et al. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Curr Med Res Opin, 2013, 29(11): 1487-1494.
26.	Zhan M, Xu T, Wu F, et al. Sitagliptin in the treatment of type 2 diabetes: a meta-analysis. J Evid Based Med, 2012, 5(3): 154-165.
27.	王瑜, 胡明, 占美, 等. 阿格列汀治疗 2 型糖尿病的系统评价. 中国医院药学杂志, 2014, 34(23): 2014-2022.
28.	Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocr Disord, 2013, 13: 9.
29.	Bekiari E, Rizava C, Athanasiadou E, et al. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine, 2016, 52(3): 458-480.
30.	占美, 吴逢波, 黄晶, 等. 维格列汀改善 2 型糖尿病患者 β 细胞功能的 Meta 分析. 中国药房, 2012, 23(6): 555-557.
31.	Cai L, Cai Y, Lu ZJ, et al. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther, 2012, 37(4): 386-398.
32.	占美, 吴逢波, 徐珽, 等. 维格列汀与其他口服降糖药对照治疗 2 型糖尿病的 Meta 分析. 中国医院药学杂志, 2011, 31(21): 1824-1828.
33.	臧彦楠, 谢振伟, 方翼. 利格列汀治疗 2 型糖尿病的系统评价. 中国临床药理学与治疗学, 2015, 20(7): 778-787.
34.	杨婷, 路敏, 周颖, 等. 利格列汀治疗 2 型糖尿病安全性的系统评价. 药品评价, 2013, 10(6): 16-20.
35.	Yao L, Fan FF, Hu L, et al. Efficacy and safety of saxagliptin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J Chin Pharm Sci, 2016, 25(2): 128-139.
36.	凌雪梅, 杨春霞. 沙格列汀改善 2 型糖尿病患者 β 细胞功能的 Meta 分析. 中国循证医学杂志, 2013, 13(4): 436-440.
37.	占美, 徐珽, 吴逢波, 等. 沙格列汀治疗 2 型糖尿病的 Meta 分析. 中国循证医学杂志, 2012, 12(6): 708-713.

1. International Diabetes Federation. IDF Diabetes Atlas 7th Edition. Available at: https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/13:diabetes-atlas-seventh-edition.html.
2. Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among men and women in China. N Engl J Med, 2010, 362(25): 2425.
3. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359(15): 1577-1589.
4. Thornberry NA, Weber AE. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem, 2007, 7 (6): 557-568.
5. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther, 2009, 26(3): 249-262.
6. Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem, 2007, 50(26): 6450-6453.
7. Feng J, Zhang ZY, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem, 2007, 50(10): 2297-2300.
8. Shea BJ, Bouter LM, Peterson J, et al. External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS One, 2007, 2(12): e1350.
9. 熊俊, 陈日新. 系统评价/Meta分析方法学质量的评价工具 AMSTAR. 中国循证医学杂志, 2011, 11(9): 1084-1089.
10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ, 2009, 339(10): e1-e34.
11. Zhou JB, Bai L, Wang Y, et al. The benefits and risks of DPP4-IV-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial. Int J Clin Pract, 2016, 70(2): 132-141.
12. Loh HH, Yee A, Loh HS, et al. Comparative studies of dipeptidyl peptidase 4 inhibitor vs. sulphonylurea among muslim type 2 diabetes patients who fast in the month of ramadan: a systematic review and meta-analysis. Prim Care Diabetes, 2016, 10(3): 210-219.
13. 李军, 唐川, 薛耀明. 胰高血糖素样肽-1 受体激动剂与二肽基肽酶-4 抑制剂治疗 2 型糖尿病的比较研究—系统评价和 Meta 分析. 中国急救医学, 2015, 35(z2): 222-225.
14. Cai X, Han X, Luo Y, et al. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on beta-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis. J Diabetes, 2015, 7(3): 347-359.
15. 周玥, 何梅, 杨明, 等. GLP-1 受体激动剂与 DPP-4 抑制剂比较治疗 2 型糖尿病效果的系统评价. 中国循证医学杂志, 2014, 14(12): 1459-1466.
16. Zhang Y, Hong J, Chi J, et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas-a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev, 2014, 30(3): 241-256.
17. Park H, Park C, Kim Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother, 2012, 46(11): 1453-1469.
18. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab, 2012, 14(12): 1061-1072.
19. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther, 2012, 34(6): 1247.
20. Monami M, Iacomelli I, Marchionni N, et al. Dipeptydil [dipeptidyl] peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis, 2010, 20(4): 224-235.
21. 徐晓菲, 吴玉波, 吴禹蒙. 西格列汀对 2 型糖尿病患者血脂水平影响的系统评价. 中国药房, 2015, 26(6): 784-787.
22. 李寅辉, 李凯利, 刘浩. 西格列汀治疗 2 型糖尿病药理作用的 Meta 分析. 循证医学, 2015, 15(3): 149-154.
23. Wang T, Gou Z, Wang F, et al. Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. PLoS One, 2014, 9(8): e103798.
24. 万里燕, 张策, 郭伟宏, 等. 西格列汀治疗 2 型糖尿病疗效和安全性的 Meta 分析. 药物不良反应杂志, 2013, 15(6): 306-313.
25. Du Q, Wu B, Wang YJ, et al. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Curr Med Res Opin, 2013, 29(11): 1487-1494.
26. Zhan M, Xu T, Wu F, et al. Sitagliptin in the treatment of type 2 diabetes: a meta-analysis. J Evid Based Med, 2012, 5(3): 154-165.
27. 王瑜, 胡明, 占美, 等. 阿格列汀治疗 2 型糖尿病的系统评价. 中国医院药学杂志, 2014, 34(23): 2014-2022.
28. Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocr Disord, 2013, 13: 9.
29. Bekiari E, Rizava C, Athanasiadou E, et al. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine, 2016, 52(3): 458-480.
30. 占美, 吴逢波, 黄晶, 等. 维格列汀改善 2 型糖尿病患者 β 细胞功能的 Meta 分析. 中国药房, 2012, 23(6): 555-557.
31. Cai L, Cai Y, Lu ZJ, et al. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther, 2012, 37(4): 386-398.
32. 占美, 吴逢波, 徐珽, 等. 维格列汀与其他口服降糖药对照治疗 2 型糖尿病的 Meta 分析. 中国医院药学杂志, 2011, 31(21): 1824-1828.
33. 臧彦楠, 谢振伟, 方翼. 利格列汀治疗 2 型糖尿病的系统评价. 中国临床药理学与治疗学, 2015, 20(7): 778-787.
34. 杨婷, 路敏, 周颖, 等. 利格列汀治疗 2 型糖尿病安全性的系统评价. 药品评价, 2013, 10(6): 16-20.
35. Yao L, Fan FF, Hu L, et al. Efficacy and safety of saxagliptin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J Chin Pharm Sci, 2016, 25(2): 128-139.
36. 凌雪梅, 杨春霞. 沙格列汀改善 2 型糖尿病患者 β 细胞功能的 Meta 分析. 中国循证医学杂志, 2013, 13(4): 436-440.
37. 占美, 徐珽, 吴逢波, 等. 沙格列汀治疗 2 型糖尿病的 Meta 分析. 中国循证医学杂志, 2012, 12(6): 708-713.

Chinese Journal of Evidence-Based Medicine

DPP-4 inhibitors for type 2 diabetes: an overview of systematic reviews

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content